{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"It was assessed by IMWG criteria. It defines complete response as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow. Very good partial response as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or \\> reduction in serum and urine M-protein level\\<100 mg per 24 hour. Partial Response as \\<=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\<=90% or to \\<200mg per 24 hr.","groups":[{"description":"Bortezomib 1.3 milligram (mg) per meter\\^2 (m\\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).","id":"OG000","title":"Bortezomib and Dexamethasone"}],"populationDescription":"The study was terminated. Due to insufficient number of participants, the outcome measure data was not analyzed.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 1, 2, 3, 4, 5, 5, 6, 7, 8 and Final/Early termination visit (30-45 days after last dose)","title":"Best Response to Treatment","type":"SECONDARY"}